Infectious Disease Research and Training Office, National Centre for Infectious Diseases, 16 Jln Tan Tock Seng, Singapore, 308442, Singapore.
Population/Global Health, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
BMC Public Health. 2024 Aug 28;24(1):2332. doi: 10.1186/s12889-024-19687-0.
Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years). We hence investigated the factors affecting awareness, acceptance, and initiative to request Paxlovid.
We assessed the Paxlovid awareness, factors impacting its uptake in a survey conducted from August 2022 to September 2022 through the SOCRATES cohort. Multivariable logistic regression was used to investigate associations between sociodemographics, perceptions, and attitudes with the key study outcomes.
Among respondents to the Paxlovid survey, 54% were aware of Paxlovid. On being provided essential details about Paxlovid, 75% reported they would likely be receptive to taking it if prescribed, and 38% indicated the initiative to request for it if it was not suggested by their doctors. Factors associated with awareness of Paxlovid include aged 40 years old and above, higher education, citing websites as an information source, greater trust in healthcare providers (aOR: 1.65, 95% CI 1.26 - 2.15) and government communications (aOR: 0.69, 95% CI 0.55 - 0.86), and higher perceived risk of COVID-19 infection (aOR: 1.25, 95% CI 1.10 - 1.42). Factors associated with acceptance to take Paxlovid include male gender, citing trust in healthcare providers (aOR: 1.49, 95% CI 1.11 - 1.99) and government communications (aOR: 1.38, 95% CI 1.09 - 1.76), and higher perceived severity of COVID-19 (aOR: 1.23, 95% CI 1.07 - 1.42). Factors associated with initiative to request Paxlovid include male gender, having pre-existing diabetes and higher perceived severity of COVID-19 (aOR: 1.24, 95% CI 1.09 - 1.40). The most common reasons for why respondents might not take Paxlovid were concerns about side effects (64%), concerns about costs (29%), and the perception that COVID-19 is a mild (25%).
The majority of our respondents would take Paxlovid if it was prescribed to them, but a much smaller proportion would have the initiative to request for this. Key factors that may influence uptake are COVID-19 threat perceptions, trust in healthcare and government, and perceptions of the drug's side effects and cost.
抗病毒治疗可以减轻 COVID-19 的负担。但即使在新加坡这样的环境下，药物的利用率也可能不理想，因为新加坡为有特定医疗条件和老年人（≥ 50 岁）提供了全面补贴。因此，我们调查了影响知晓率、接受度和主动要求使用帕克洛维德的因素。
我们通过 SOCRATES 队列在 2022 年 8 月至 2022 年 9 月期间进行的一项调查，评估了 Paxlovid 的知晓率以及影响其使用的因素。多变量逻辑回归用于研究社会人口统计学、认知和态度与关键研究结果之间的关联。
在接受 Paxlovid 调查的受访者中，有 54%的人知晓 Paxlovid。在提供有关 Paxlovid 的基本详细信息后，有 75%的人表示如果医生开处方，他们很可能愿意服用，而 38%的人表示如果医生没有建议服用，他们会主动要求服用。与知晓 Paxlovid 相关的因素包括年龄在 40 岁及以上、接受过高等教育、将网站作为信息来源、对医疗保健提供者的信任度更高（OR：1.65，95%CI 1.26-2.15）和政府沟通（OR：0.69，95%CI 0.55-0.86），以及对 COVID-19 感染的感知风险更高（OR：1.25，95%CI 1.10-1.42）。与接受服用 Paxlovid 相关的因素包括男性、对医疗保健提供者的信任度（OR：1.49，95%CI 1.11-1.99）和政府沟通（OR：1.38，95%CI 1.09-1.76），以及对 COVID-19 的严重程度的感知更高（OR：1.23，95%CI 1.07-1.42）。与主动要求服用 Paxlovid 相关的因素包括男性、患有糖尿病前期和对 COVID-19 严重程度的感知更高（OR：1.24，95%CI 1.09-1.40）。受访者可能不服用 Paxlovid 的最常见原因是担心副作用（64%）、担心费用（29%）以及认为 COVID-19 是轻度的（25%）。
我们的大多数受访者如果医生开处方，会服用 Paxlovid，但只有一小部分人会主动要求服用。可能影响药物使用的关键因素是对 COVID-19 威胁的认知、对医疗保健和政府的信任以及对药物副作用和费用的认知。
